Vogenx, Inc. (VOGX)
Vogenx will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Company Description
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Our company was founded in 2021 by experienced leaders with proven expertise developing drugs in the metabolic disease space.
Our primary objective is to advance our lead investigational product candidate, mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1, or SGLT1, through clinical development for disorders related to glucose absorption and postprandial dysregulation, through clinical development and towards regulatory approval.
Vogenx, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | James Green |
Contact Details
Address: PO Box 19469 Raleigh, NC 27619 United States | |
| Phone | (919) 659-5677 |
| Website | vogenx.com |
Stock Details
| Ticker Symbol | VOGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1903784 |
| Employer ID | 86-3697324 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James Green | President, Chief Executive Officer and Director |
| William Wilkison, Ph.D. | Chief Scientific Officer and Director |
| Steven Delmar | Chief Financial Officer, Corporate Secretary and Director |
| Timothy Boris | Director |
| Richard Gorman | Director |
| Peter Pieraccini | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 30, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 2, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Feb 20, 2026 | DRS | [Cover] Draft Registration Statement |
| Jan 7, 2026 | D | Notice of Exempt Offering of Securities |